Stock 2196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Delayed Hong Kong S.E.
Other stock markets
 10:55:59 2024-04-29 pm EDT 		5-day change 1st Jan Change
12.28 HKD -0.81% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +4.25% -27.88%
Apr. 29 Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator
MT
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
MT
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator
MT
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs
MT
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners
CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration
MT
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug
MT
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate
MT
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan
MT
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs
MT
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator
MT
Yuyuan Tourist Mart CFO Steps Down
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 2196 Stock
  5. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.